Mentice AB (publ) (MNTC.ST)
SEK 25.3
(1.61%)
SEK 25.3
(1.61%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 273.61 Million SEK | 25.54% |
| 2022 | 217.95 Million SEK | 17.77% |
| 2021 | 185.06 Million SEK | 34.59% |
| 2020 | 137.5 Million SEK | -7.94% |
| 2019 | 149.37 Million SEK | -4.89% |
| 2018 | 157.04 Million SEK | 44.13% |
| 2017 | 108.96 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 100.99 Million SEK | 122.31% |
| 2024 Q1 | 45.42 Million SEK | -35.5% |
| 2023 Q2 | 74.31 Million SEK | 14.39% |
| 2023 Q1 | 64.96 Million SEK | -5.38% |
| 2023 FY | 273.61 Million SEK | 25.54% |
| 2023 Q4 | 70.43 Million SEK | 10.23% |
| 2023 Q3 | 63.89 Million SEK | -14.02% |
| 2022 Q2 | 45.11 Million SEK | -15.02% |
| 2022 Q1 | 53.08 Million SEK | -21.57% |
| 2022 FY | 217.95 Million SEK | 17.77% |
| 2022 Q4 | 68.65 Million SEK | 34.36% |
| 2022 Q3 | 51.1 Million SEK | 13.28% |
| 2021 Q1 | 32.32 Million SEK | -29.65% |
| 2021 Q2 | 46.38 Million SEK | 43.52% |
| 2021 Q4 | 67.68 Million SEK | 75.03% |
| 2021 Q3 | 38.67 Million SEK | -16.63% |
| 2021 FY | 185.06 Million SEK | 34.59% |
| 2020 Q4 | 45.94 Million SEK | 37.42% |
| 2020 Q3 | 33.43 Million SEK | 37.31% |
| 2020 Q2 | 24.34 Million SEK | -27.93% |
| 2020 Q1 | 33.78 Million SEK | -43.92% |
| 2020 FY | 137.5 Million SEK | -7.94% |
| 2019 FY | 149.37 Million SEK | -4.89% |
| 2019 Q4 | 60.24 Million SEK | 105.63% |
| 2019 Q3 | 29.29 Million SEK | -9.45% |
| 2019 Q2 | 32.35 Million SEK | 17.73% |
| 2019 Q1 | 27.48 Million SEK | -57.84% |
| 2018 Q2 | 27.96 Million SEK | -1.13% |
| 2018 Q3 | 35.6 Million SEK | 27.32% |
| 2018 Q4 | 65.18 Million SEK | 83.07% |
| 2018 FY | 157.04 Million SEK | 44.13% |
| 2018 Q1 | 28.28 Million SEK | 0.0% |
| 2017 FY | 108.96 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -4284.073% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 80.072% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 80.072% |
| Arcoma AB | 163.01 Million SEK | -67.843% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | -34.129% |
| BICO Group AB (publ) | 2.23 Billion SEK | 87.783% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 52.11% |
| CellaVision AB (publ) | 677.29 Million SEK | 59.602% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -3207.265% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -27925.743% |
| C-Rad AB (publ) | 424.61 Million SEK | 35.563% |
| Duearity AB (publ) | 1.65 Million SEK | -16442.322% |
| Dignitana AB (publ) | 86.06 Million SEK | -217.918% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -2556.408% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.14% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -3765.483% |
| Integrum AB (publ) | 104.11 Million SEK | -162.787% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -31912.439% |
| OssDsign AB (publ) | 112.15 Million SEK | -143.953% |
| Paxman AB (publ) | 210.11 Million SEK | -30.218% |
| Promimic AB (publ) | 37.07 Million SEK | -638.09% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -112035.246% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -1077.07% |
| ScandiDos AB (publ) | 60.42 Million SEK | -352.779% |
| Sectra AB (publ) | 2.96 Billion SEK | 90.768% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -77.822% |
| Senzime AB (publ) | 35.75 Million SEK | -665.257% |
| SpectraCure AB (publ) | 318 Thousand SEK | -85940.881% |
| Stille AB | 294.89 Million SEK | 7.217% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 92.209% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 54.211% |